Update Series (2025) Lesson 18: Multidisciplinary Evaluation and Management of Pelvic Pain in Women

Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice

CME Available: https://auau.auanet.org/node/43029

At the conclusion of this activity, participants will be able to:

1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer

2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation

3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer

4. Discern the different prognostic endpoints provided by various genomic tests

5. Recognize candidates for, and implications of, germline testing for prostate cancer.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems 

CME Available: https://auau.auanet.org/node/43047

At the conclusion of this activity, participants will be able to:

1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills.

2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage.

3. Identify methods to treat significant toxicities from various intravesical therapies.

4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.

5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.

ACKNOWLEDGEMENTS:

This educational activity is supported by an independent educational grants from:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

The Surgical Management of BPH (2025)

CME Available: https://auau.auanet.org/node/43193

Acknowledgements: This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.

After participating in this CME activity, participants will be able to:

1. Utilize the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.

2. Determine the appropriate role and clinical expectation for current technologies, including pivotal studies, based on evidence.

3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.

4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.

AUA2025: AUA Advanced Prostate Cancer Course

CME Available: https://auau.auanet.org/node/43035

At the conclusion of this activity, participants will be able to:

1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling.

2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations.

3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC.

4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines.

5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities

CME Available: https://auau.auanet.org/node/43003

At the conclusion of this activity, participants will be able to:

1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.

2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images

3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.

4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.

5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing Harm

CME Available: https://auau.auanet.org/node/43021

At the conclusion of this activity, participants will be able to:

1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.

2. Maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers.

3. Describe the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.

4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used.

5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice

CME Available: https://auau.auanet.org/node/43015

At the conclusion of this activity, participants will be able to:

1. Describe key components of genetic risk assessment, genetic counseling, and informed consent for genetic testing.

2. Describe elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability.

3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic results in prostate cancer screening and management of both localized and advanced prostate cancer.

4. Describe genetic causes, clinical manifestations, indication for genetic testing, and cancer risk associated with hereditary kidney cancer syndromes. Understand how genetic mutation can guide targeted therapy in patients with von Hippel-Lindau syndrome.

5. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Highlights from AUA2025: Advances in NMIBC (2025)

CME Available: https://auau.auanet.org/node/43167

At the conclusion of this CME activity, participants will be able to:

1. Recognize recent developments in the management of NMIBC.

2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events.

3. Employ current management approaches for NMIBC.

4. Utilize risk stratification to guide treatment decisions for NMIBC patients.

5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.

This educational activity is supported by independent educational grants from:

Merck & Co., Inc.

ImmunityBio, Inc.

AUA Guidelines: Microhematuria

Co-Hosts: Daniel A. Barocas, MD, MPH & Stephen Boorjian, MD

Microhematuria: AUA/SUFU Guideline (2025)

Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490. https://www.auajournals.org/doi/abs/10.1097/JU.0000000000004490